Key Takeaways
- • Venture capital investment in women's health startups reached $2.6 billion in 2024, representing a 55% year-over-year increase and surpassing 2023 totals by nearly $1 billion, according to Silicon Valley Bank's 2025 Innovation in Women's Health Report.
- • When including funding for diseases that disproportionately affect women or manifest differently in female populations, total sector investment climbed to $10.7 billion in 2024, demonstrating broader institutional recognition of unmet healthcare needs in women's health.
- • The 2024 growth significantly outpaced the broader healthcare venture capital sector, positioning women's health as a high-conviction investment thesis despite acknowledged challenges in the overall fundraising environment.
- • Silicon Valley Bank (now a division of First Citizens Bank) attributed the expansion to increased awareness of how health conditions impact women differently, with analyst expectations for continued long-term investment momentum despite potential 2025 headwinds.
Summary
Venture capital investment in women's health startups demonstrated substantial momentum in 2024, reaching $2.6 billion and marking a decisive inflection point for the sector. According to Silicon Valley Bank's 2025 Innovation in Women's Health Report released April 2, 2025, this figure represented a 55% increase compared to 2023 and exceeded the prior year's total by nearly $1 billion. The growth trajectory is particularly notable given the broader venture capital market's challenging fundraising environment during the period.
The expansion extends beyond narrowly defined women's health companies. When factoring in venture capital allocated to diseases that affect women disproportionately or manifest with different clinical characteristics in female populations, total sector investment reached $10.7 billion in 2024. This distinction underscores the widening investor perception of opportunities across interconnected therapeutic areas and disease management approaches tailored to female populations.
The sector's outperformance relative to the broader healthcare venture capital landscape reflects a fundamental reshift in institutional conviction regarding women's health investment risk-return profiles. Raysa Bousleiman, co-author of the report and senior vice president for Investor Coverage in Life Science and Healthcare at Silicon Valley Bank, attributed the acceleration to "growing recognition of the ways in which health conditions impact women differently." This sentiment suggests that years of advocacy highlighting structural underinvestment and evidence gaps in women's health research have begun translating into concrete capital allocation decisions.
While Silicon Valley Bank acknowledged potential near-term challenges for 2025, analyst commentary reflected confidence in the sector's long-term investment trajectory. The bank's assessment emphasized that continued capital deployment is expected to address persistent unmet healthcare needs in women's health, positioning the sector favorably for sustained institutional interest in subsequent funding cycles.
The expansion extends beyond narrowly defined women's health companies. When factoring in venture capital allocated to diseases that affect women disproportionately or manifest with different clinical characteristics in female populations, total sector investment reached $10.7 billion in 2024. This distinction underscores the widening investor perception of opportunities across interconnected therapeutic areas and disease management approaches tailored to female populations.
The sector's outperformance relative to the broader healthcare venture capital landscape reflects a fundamental reshift in institutional conviction regarding women's health investment risk-return profiles. Raysa Bousleiman, co-author of the report and senior vice president for Investor Coverage in Life Science and Healthcare at Silicon Valley Bank, attributed the acceleration to "growing recognition of the ways in which health conditions impact women differently." This sentiment suggests that years of advocacy highlighting structural underinvestment and evidence gaps in women's health research have begun translating into concrete capital allocation decisions.
While Silicon Valley Bank acknowledged potential near-term challenges for 2025, analyst commentary reflected confidence in the sector's long-term investment trajectory. The bank's assessment emphasized that continued capital deployment is expected to address persistent unmet healthcare needs in women's health, positioning the sector favorably for sustained institutional interest in subsequent funding cycles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.